<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01154543</url>
  </required_header>
  <id_info>
    <org_study_id>Famvir™ 500 in HIV</org_study_id>
    <nct_id>NCT01154543</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Famciclovir in HIV1 Positive Adults With Recurrent Genital Herpes</brief_title>
  <official_title>A Single Center, Open Label, Longitudinal Single Arm Study to Compare the Efficacy and Safety of Prophylactic Famciclovir 500 mg b.d. in HIV Positive Adults With Recurrent Genital Herpes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Holdsworth House Medical Practice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Holdsworth House Medical Practice</source>
  <brief_summary>
    <textblock>
      To determine the efficacy of Famvir 500mg bd as suppressive antiviral therapy for acute
      genital Herpes simplex virus (HSV) outbreaks in HIV subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the incidence of acute genital HSV outbreaks whilst taking Famciclovir 500 mg bd during the study period (24 months)</measure>
    <time_frame>24 months</time_frame>
    <description>To determine the incidence of acute genital HSV outbreaks whilst taking Famciclovir 500 mg bd during the study period (24 months)and to determine the safety of Famciclovir 500mg bd in this population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the acceptability of Famciclovir 500 mg bd as long term suppressive antiviral therapy</measure>
    <time_frame>24 months</time_frame>
    <description>To determine the acceptability of Famciclovir 500 mg bd as long term suppressive antiviral therapy To determine virological &amp; immunological parameters of HIV whilst taking Famciclovir 500 mg as suppressive antiviral therapy To determine patient adherence to Famciclovir 500 mg bd over the study period To determine the incidence of oral HSV outbreaks in subjects taking Famciclovir 500 mg bd as suppressive antiviral therapy</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">42</enrollment>
  <condition>HIV Positive</condition>
  <condition>Herpes Simplex, Genital</condition>
  <arm_group>
    <arm_group_label>HIV positive, gential HSV,Famvir™ 500mg bd, suppressive</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        50-60 patients attending Holdsworth House Medical Practice in Darlinghurst, Sydney, New
        South Wales with documented HIV-1 infection who are taking Famciclovir 500mg bd as
        suppressive therapy for management of genital HSV infection who agree to participate in
        this study will be enrolled after signing HREC approved informed consent.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide signed informed consent

          -  Documented HIV infection

          -  In general good health, without other serious medical conditions as deemed by the
             investigator

          -  Male or female over 18 years of age

          -  Diagnosed genital HSV (clinical or laboratory)

          -  Life expectancy of 12 months or longer per investigator's judgment

          -  Stable on Famvir 500 mg bd for at least 30 days at time of screening

        Exclusion Criteria:

          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive hCG laboratory test (&gt;5)mIU/mL).

          -  Women of childbearing potential who are unwilling to use reliable contraception for
             the duration of the study.

          -  History of hypersensitivity to Famvir, its constituents or penciclovir

          -  Current use of another antiherpetic medication

          -  Recent history of alcohol or drug abuse, which in the opinion of the investigator may
             interfere with their compliance with study requirements, or who have any other
             conditions which in the opinion of the investigator would interfere with the
             successful completion of study procedures

          -  Disorder or condition that could interfere with drug absorption, distribution,
             metabolism or excretion

          -  Known or suspected to have or past history of renal dysfunction requiring a dosage
             modification of Famvir 500 bd
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark T Bloch, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Australian Health Practitioners Regulation authority</affiliation>
  </overall_official>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2010</study_first_submitted>
  <study_first_submitted_qc>June 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2010</study_first_posted>
  <last_update_submitted>March 19, 2013</last_update_submitted>
  <last_update_submitted_qc>March 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Holdsworth House Medical Practice</investigator_affiliation>
    <investigator_full_name>Dr. Mark Bloch</investigator_full_name>
    <investigator_title>Dr Mark Bloch</investigator_title>
  </responsible_party>
  <keyword>Recurrent genital Herpes Simplex Virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Seropositivity</mesh_term>
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Herpes Genitalis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Famciclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

